Zevra Therapeutics (NASDAQ:ZVRA) Issues Earnings Results

Zevra Therapeutics (NASDAQ:ZVRA) released its earnings results on Wednesday. The company reported $0.25 earnings per share for the quarter, beating analysts’ consensus estimates of $0.11 by $0.14, FiscalAI reports. Zevra Therapeutics had a net margin of 101.58% and a return on equity of 51.49%. The firm had revenue of $39.66 million for the quarter, compared to analysts’ expectations of $33.88 million.

Here are the key takeaways from Zevra Therapeutics’ conference call:

• Second-quarter revenue rose 53% year over year to $39.7 million, driven by $30.2 million in U.S. MIPLYFFA sales, which increased 23% sequentially and 40% year over year.
• MIPLYFFA enrollment reached 184 prescription forms through June 30, including 23 in the first half of 2026, with a diverse mix of newly and previously diagnosed patients, children and adults, and specialty-center and community-practice prescribers.
• Zevra requested an EMA re-examination of arimoclomol’s negative CHMP opinion and expects a decision in the fourth quarter; management cited long-term, pediatric, expanded-access, and safety data as support, but approval remains uncertain.
• Celiprolol’s Phase III DISCOVER trial remains early and event-driven, with 66 of 150 patients enrolled and only three confirmed events versus the 28 needed for interim analysis, prompting efforts to accelerate enrollment and regulatory discussions.
• Cash, cash equivalents, and investments totaled $260.2 million at quarter-end, up approximately $23.4 million sequentially, giving Zevra flexibility to fund MIPLYFFA expansion, celiprolol, and potential external opportunities without relying on capital markets.

Zevra Therapeutics Trading Up 13.1%

Shares of ZVRA stock traded up $1.38 during trading on Thursday, reaching $11.91. 1,872,350 shares of the company’s stock traded hands, compared to its average volume of 1,364,082. The firm’s 50-day moving average is $12.31 and its 200 day moving average is $10.55. The company has a market capitalization of $703.88 million, a P/E ratio of 5.96 and a beta of 0.91. Zevra Therapeutics has a 1 year low of $7.16 and a 1 year high of $15.03.

Key Zevra Therapeutics News

Here are the key news stories impacting Zevra Therapeutics this week:

• Positive Sentiment: Analyst raises price target: Citizens JMP lifted its ZVRA price target from $25 to $28 and maintained a “market outperform” rating, implying substantial upside from recent trading levels. Benzinga
• Positive Sentiment: MIPLYFFA regulatory and patent support: Zevra said the CHMP reexamination process is progressing, with a European opinion expected in the fourth quarter. The company also reported that MIPLYFFA’s Orange Book listing extends to 2041, potentially strengthening the product’s long-term commercial protection. CHMP reexamination and Orange Book update
• Positive Sentiment: Quarterly results exceeded expectations: Second-quarter revenue reached approximately $39.7 million, up 53% year over year and ahead of analyst estimates, including $30.2 million from MIPLYFFA. Reported EPS also surpassed consensus estimates. Zevra highlighted a strong cash position of $260.2 million, providing resources to support commercialization and development activities. Zevra second-quarter financial results
• Neutral Sentiment: Institutional positioning is mixed: Recent filings show several funds adding shares, including Point72, AIGH Capital and FMR, while other institutions reduced their positions. This signals continued investor interest but also significant ownership turnover.
• Negative Sentiment: Insider selling and legal investigation: Company insiders reported sales and no purchases during the referenced six-month period. Separately, Pomerantz LLP announced an investigation into potential investor claims, creating a reputational and litigation overhang. Pomerantz investor alert

Analyst Ratings Changes

A number of equities research analysts recently commented on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $26.00 price target on shares of Zevra Therapeutics in a report on Tuesday, June 23rd. Maxim Group increased their price objective on Zevra Therapeutics from $25.00 to $35.00 and gave the company a “buy” rating in a report on Wednesday, June 10th. Citigroup reissued an “outperform” rating on shares of Zevra Therapeutics in a research report on Thursday. Wall Street Zen raised Zevra Therapeutics from a “hold” rating to a “buy” rating in a research report on Sunday, July 12th. Finally, Guggenheim cut their price target on Zevra Therapeutics from $29.00 to $24.00 and set a “buy” rating for the company in a research note on Monday, July 27th. Nine investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat.com, Zevra Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $27.29.

Institutional Investors Weigh In On Zevra Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of ZVRA. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of Zevra Therapeutics by 6.1% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 31,761 shares of the company’s stock worth $238,000 after acquiring an additional 1,812 shares during the period. Strs Ohio bought a new stake in shares of Zevra Therapeutics during the 1st quarter valued at $125,000. Creative Planning purchased a new stake in Zevra Therapeutics during the 2nd quarter worth about $92,000. Rhumbline Advisers boosted its stake in Zevra Therapeutics by 11.6% in the 2nd quarter. Rhumbline Advisers now owns 83,221 shares of the company’s stock worth $733,000 after purchasing an additional 8,636 shares during the period. Finally, Quantbot Technologies LP bought a new position in Zevra Therapeutics in the 2nd quarter worth about $255,000. Institutional investors own 35.03% of the company’s stock.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome.